Expertise in
7
conditions

Dr. Ronald T. Mitsuyasu

Internal Medicine
The Regents Of The University Of California
200 Medical Plz, 
Los Angeles, CA 
Clinical Trials:Currently Recruiting for 1 Trial
Expertise in
7
conditions
The Regents Of The University Of California
200 Medical Plz, 
Los Angeles, CA 

Overview

Ronald Mitsuyasu is a primary care provider, practicing in Internal Medicine in Los Angeles, California.

Dr. Mitsuyasu is highly rated in 7 conditions, according to our data. His clinical expertise encompasses Kaposi Sarcoma, HIV/AIDS, Anal Cancer, and Squamous Cell Carcinoma of the Anal Canal (SCAC).

He is actively involved in clinical research, co-authoring 63 peer reviewed articles and participating in 14 clinical trials.

Specialties

Internal Medicine

Licenses

Internal Medicine in CA

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID

Locations

The Regents of the University of California
200 Medical Plz, Los Angeles, CA 90095

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

13 Clinical Trials

A Phase 2 Trial of Ixazomib for Kaposi Sarcoma
A Phase 2 Trial of Ixazomib for Kaposi Sarcoma
Enrollment Status: Recruiting
Publish Date: February 27, 2026
Intervention Type: Other, Drug
Study Drug: Ixazomib Citrate
Study Phase: Phase 2
A Pilot Study of Ibrutinib and R-da-EPOCH for Front Line Treatment of AIDS-Related Lymphomas
A Pilot Study of Ibrutinib and R-da-EPOCH for Front Line Treatment of AIDS-Related Lymphomas
Enrollment Status: Active_not_recruiting
Publish Date: August 11, 2026
Intervention Type: Drug, Biological, Other
Study Drugs: Cyclophosphamide, Doxorubicin Hydrochloride, Etoposide, Filgrastim, Ibrutinib, Pegfilgrastim, Prednisone, Rituximab, Vincristine Sulfate
Study Phase: Phase 1
A Phase 2 Evaluation of VGX-3100, a Synthetic DNA Immunotherapy Targeting Human Papillomavirus 16 and 18 E6 and E7 Proteins, for Anal High-Grade Squamous Intraepithelial Lesions (HSIL) in HIV-Positive Individuals
A Phase 2 Evaluation of VGX-3100, a Synthetic DNA Immunotherapy Targeting Human Papillomavirus 16 and 18 E6 and E7 Proteins, for Anal High-Grade Squamous Intraepithelial Lesions (HSIL) in HIV-Positive Individuals
Enrollment Status: Completed
Publish Date: July 08, 2026
Intervention Type: Device, Other, Biological
Study Drug: HPV DNA Plasmids Therapeutic Vaccine VGX-3100
Study Phase: Phase 2
A Phase II Study of sEphB4-HSA in Kaposi Sarcoma
A Phase II Study of sEphB4-HSA in Kaposi Sarcoma
Enrollment Status: Completed
Publish Date: June 01, 2026
Intervention Type: Behavioral, Other, Biological
Study Drug: Recombinant EphB4-HSA Fusion Protein
Study Phase: Phase 2
A Phase I Study of Ipilimumab and Nivolumab in Advanced HIV Associated Solid Tumors With Expansion Cohort in HIV Associated Solid Tumors and a Cohort of HIV-Associated Classical Hodgkin Lymphoma
A Phase I Study of Ipilimumab and Nivolumab in Advanced HIV Associated Solid Tumors With Expansion Cohort in HIV Associated Solid Tumors and a Cohort of HIV-Associated Classical Hodgkin Lymphoma
Enrollment Status: Terminated
Publish Date: January 21, 2026
Intervention Type: Biological, Procedure
Study Drugs: Ipilimumab, Nivolumab
Study Phase: Phase 1
A Pilot Study of Nelfinavir for the Treatment of Kaposi Sarcoma
A Pilot Study of Nelfinavir for the Treatment of Kaposi Sarcoma
Enrollment Status: Completed
Publish Date: December 17, 2025
Intervention Type: Other, Drug
Study Drug: Nelfinavir Mesylate
Study Phase: Phase 2
A Pilot Study to Evaluate the Feasibility, Safety and Engraftment of Zinc Finger Nuclease (ZFN) CCR5 Modified CD34+ Hematopoietic Stem/Progenitor Cells (SB-728mR-HSPC) in HIV-1 (R5) Infected Patients
A Pilot Study to Evaluate the Feasibility, Safety and Engraftment of Zinc Finger Nuclease (ZFN) CCR5 Modified CD34+ Hematopoietic Stem/Progenitor Cells (SB-728mR-HSPC) in HIV-1 (R5) Infected Patients
Enrollment Status: Active_not_recruiting
Publish Date: October 09, 2025
Intervention Type: Genetic
Study Phase: Phase 1
A Pilot Trial of AVD and Brentuximab Vedotin (SGN-35) in the Treatment of Stage II-IV HIV-Associated Hodgkin Lymphoma
A Pilot Trial of AVD and Brentuximab Vedotin (SGN-35) in the Treatment of Stage II-IV HIV-Associated Hodgkin Lymphoma
Enrollment Status: Completed
Publish Date: August 15, 2025
Intervention Type: Drug, Other
Study Drugs: Brentuximab, Dacarbazine, Doxorubicin, Vinblastine
Study Phase: Phase 1/Phase 2
A Randomized, Phase III Study of Intra-anal Imiquimod 2.5% vs. Topical 5-fluorouracil 5% vs. Observation for the Treatment of High-grade Anal Squamous Intraepithelial Lesions in HIV-infected Men and Women
A Randomized, Phase III Study of Intra-anal Imiquimod 2.5% vs. Topical 5-fluorouracil 5% vs. Observation for the Treatment of High-grade Anal Squamous Intraepithelial Lesions in HIV-infected Men and Women
Enrollment Status: Completed
Publish Date: July 23, 2025
Intervention Type: Drug, Other
Study Drugs: Imiquimod, Fluorouracil
Study Phase: Phase 3
Clinical and Genomic Factors for Prognosis of AIDS Primary Effusion Lymphoma
Clinical and Genomic Factors for Prognosis of AIDS Primary Effusion Lymphoma
Enrollment Status: Terminated
Publish Date: May 11, 2025
Intervention Type: Other, Genetic
View 9 Less Clinical Trials

63 Total Publications

Early antiretroviral therapy and long-term cancer risk in HIV: 9-year outcomes from the START randomized trial.
Early antiretroviral therapy and long-term cancer risk in HIV: 9-year outcomes from the START randomized trial.
Journal: BMC cancer
Published: October 13, 2025
Similar Doctors
Expertise in
18
conditions
Dr. Charles N. Bernstein
Internal Medicine
Expertise in
18
conditions
Dr. Charles N. Bernstein
Internal Medicine

The Regents Of The University Of California

200 Medical Plz, 
Los Angeles, CA 
 (0.1 miles away)
310-794-9718
Languages Spoken:
English

Charles Bernstein is a primary care provider, practicing in Internal Medicine in Los Angeles, California. Dr. Bernstein is highly rated in 18 conditions, according to our data. His clinical expertise encompasses Viral Gastroenteritis, Crohn's Disease, Colitis, Colonoscopy, and Endoscopy.

Expertise in
28
conditions
Dr. Michael H. Albert
Internal Medicine
Expertise in
28
conditions
Dr. Michael H. Albert
Internal Medicine

Cedars-Sinai Medical Center

8700 Beverly Blvd, 
West Hollywood, CA 
 (3.8 miles away)
310-423-5161
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Michael Albert is a primary care provider, practicing in Internal Medicine in West Hollywood, California. Dr. Albert is highly rated in 28 conditions, according to our data. His clinical expertise encompasses Nijmegen Breakage Syndrome, Wiskott-Aldrich Syndrome, Hyper IgE Syndrome, Splenectomy, and Bone Graft. Dr. Albert is currently accepting new patients.

Expertise in
16
conditions
Dr. Abbas Ardehali
Internal Medicine
Expertise in
16
conditions
Dr. Abbas Ardehali
Internal Medicine

Office

100 Medical Plz E Ste 630, 
Los Angeles, CA 
 (0.5 miles away)
310-206-8232
Languages Spoken:
English
See accepted insurances

Abbas Ardehali is a primary care provider, practicing in Internal Medicine in Los Angeles, California. Dr. Ardehali is highly rated in 16 conditions, according to our data. His clinical expertise encompasses Acute Interstitial Pneumonia, Hypersensitivity Pneumonitis, Bronchiolitis Obliterans, Lung Transplant, and Heart Transplant.

Frequently Asked Questions about Dr. Ronald T. Mitsuyasu

How do I make an appointment with Dr. Ronald T. Mitsuyasu?

You can book an appointment with Dr. Ronald T. Mitsuyasu by calling their office at 310-794-9718. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Ronald T. Mitsuyasu a top-rated expert for Kaposi Sarcoma?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Ronald T. Mitsuyasu is classified as an Distinguished expert for Kaposi Sarcoma, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Ronald T. Mitsuyasu specialize in?

While Dr. Ronald T. Mitsuyasu is a Internal Medicine, they have specific expertise in Kaposi Sarcoma, HIV/AIDS, and Anal Cancer. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Internal Medicine.

Does Dr. Ronald T. Mitsuyasu participate in research or clinical trials?

Yes. Dr. Ronald T. Mitsuyasu has published 63 articles and abstracts on conditions like Kaposi Sarcoma. You can view a list of Dr. Ronald T. Mitsuyasu's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Ronald T. Mitsuyasu accept my insurance?

Dr. Ronald T. Mitsuyasu accepts most major insurance plans, including Medicaid. We recommend calling the office directly at 310-794-9718 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Mitsuyasu's expertise for a condition
ConditionClose
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile